S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 4/12/2024
5 Trends You Need to Know This Quarter
MarketBeat Week in Review – 4/8 - 4/12
Faced with possibly paying for news, Google removes links to California news sites for some users
The US and UK restrict the trade of Russian-origin metals
US Steel shareholders approve takeover by Japan's Nippon Steel opposed by Biden administration
NASDAQ:SRDX

Surmodics (SRDX) Stock Price, News & Analysis

$27.00
-0.68 (-2.46%)
(As of 04/12/2024 ET)
Today's Range
$26.86
$27.97
50-Day Range
$26.96
$34.08
52-Week Range
$16.79
$39.41
Volume
79,493 shs
Average Volume
59,235 shs
Market Capitalization
$384.48 million
P/E Ratio
71.05
Dividend Yield
N/A
Price Target
$59.00

Surmodics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
118.5% Upside
$59.00 Price Target
Short Interest
Bearish
3.28% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.52
Upright™ Environmental Score
News Sentiment
0.87mentions of Surmodics in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.90) to ($0.02) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.31 out of 5 stars

Medical Sector

129th out of 923 stocks

Surgical & Medical Instruments Industry

20th out of 97 stocks

SRDX stock logo

About Surmodics Stock (NASDAQ:SRDX)

Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

SRDX Stock Price History

SRDX Stock News Headlines

Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
SYK Jun 2024 290.000 put
SurModics (SRDX) Reports Break-Even Earnings for Q1
A Preview Of Surmodics's Earnings
Returns Are Gaining Momentum At Surmodics (NASDAQ:SRDX)
See More Headlines
Receive SRDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surmodics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/06/2023
Today
4/13/2024
Next Earnings (Estimated)
4/24/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:SRDX
CUSIP
86887310
Employees
376
Year Founded
1979

Price Target and Rating

Average Stock Price Target
$59.00
High Stock Price Target
$71.00
Low Stock Price Target
$47.00
Potential Upside/Downside
+118.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-1,540,000.00
Pretax Margin
7.07%

Debt

Sales & Book Value

Annual Sales
$132.58 million
Cash Flow
$0.76 per share
Book Value
$8.48 per share

Miscellaneous

Free Float
12,969,000
Market Cap
$384.48 million
Optionable
Optionable
Beta
1.01

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

SRDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Surmodics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surmodics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SRDX shares.
View SRDX analyst ratings
or view top-rated stocks.

What is Surmodics' stock price target for 2024?

2 analysts have issued 12-month price objectives for Surmodics' stock. Their SRDX share price targets range from $47.00 to $71.00. On average, they predict the company's stock price to reach $59.00 in the next year. This suggests a possible upside of 118.5% from the stock's current price.
View analysts price targets for SRDX
or view top-rated stocks among Wall Street analysts.

How have SRDX shares performed in 2024?

Surmodics' stock was trading at $36.35 at the beginning of the year. Since then, SRDX shares have decreased by 25.7% and is now trading at $27.00.
View the best growth stocks for 2024 here
.

When is Surmodics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 24th 2024.
View our SRDX earnings forecast
.

How were Surmodics' earnings last quarter?

Surmodics, Inc. (NASDAQ:SRDX) posted its quarterly earnings results on Monday, February, 6th. The company reported ($0.50) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.13. The business earned $24.93 million during the quarter, compared to analysts' expectations of $24.19 million. Surmodics had a trailing twelve-month return on equity of 8.06% and a net margin of 3.99%. During the same quarter last year, the company earned ($0.13) earnings per share.

What guidance has Surmodics issued on next quarter's earnings?

Surmodics updated its FY 2024 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of -1.170--0.870 for the period, compared to the consensus estimate of -1.160. The company issued revenue guidance of $113.0 million-$117.0 million, compared to the consensus revenue estimate of $119.3 million.

What is Gary Maharaj's approval rating as Surmodics' CEO?

8 employees have rated Surmodics Chief Executive Officer Gary Maharaj on Glassdoor.com. Gary Maharaj has an approval rating of 65% among the company's employees.

What other stocks do shareholders of Surmodics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surmodics investors own include Gilead Sciences (GILD), Netflix (NFLX), Exelixis (EXEL), Intel (INTC), NVIDIA (NVDA), Tandem Diabetes Care (TNDM), uniQure (QURE), Sangamo Therapeutics (SGMO), Abbott Laboratories (ABT) and Dynavax Technologies (DVAX).

Who are Surmodics' major shareholders?

Surmodics' stock is owned by a number of institutional and retail investors. Top institutional investors include Salem Investment Counselors Inc. (0.85%). Insiders that own company stock include Charles W Olson, Charles W Olson, David Dantzker, Gary R Maharaj, John D Manders, Jose H Bedoya, Joseph J Stich, Joseph J Stich and Ronald B Sr Kalich Sr.
View institutional ownership trends
.

How do I buy shares of Surmodics?

Shares of SRDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SRDX) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners